Open AccessUse of non-steroidal anti-inflammatory drugs during the COVID-19 pandemic. Resolution of the Expert Council of the Russian Society for the Prevention of Noncommunicable Diseases
Author(s) -
О. М. Drapkina,
S. N. Avdeev,
А.V. Gorelov,
Vladimir Chulanov,
Л. И. Алексеева,
А. Б. Данилов,
Г. Р. Табеева,
M. V. Pchelintsev
Publication year - 2022
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2022-3187
Subject(s) - pandemic , covid-19 , medicine , nonsteroidal , intensive care medicine , dilemma , coronavirus , public health , disease , pharmacology , virology , infectious disease (medical specialty) , pathology , outbreak , philosophy , epistemology
The spread and consequences of the coronavirus disease 2019 (COVID-19) pandemic are currently one of the most pressing public health challenges in the world. Despite the fact that experience accumulates in the treatment and monitoring of COVID-19 patients, certain aspects are still a clinical dilemma. In particular, this regarded the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the pandemic, both as a symptomatic treatment of infection, and in patients with comorbidities requiring NSAID. A series of studies did not establish evidence of the risk of infection and complications from NSAID therapy in COVID-19. At the same time, the practitioner should take into account the risk of specific NSAID-associated complications, which also remain relevant during the COVID-19 pandemic. This resolution focuses on the evolution of ideas about NSAID use and safety in COVID-19, and also emphasizes the particular relevance of their use for a number of clinical situations.